Published in BMJ on June 12, 1993
Active cascade testing for carriers of cystic fibrosis gene. BMJ (1994) 3.10
Cost effectiveness of antenatal screening for cystic fibrosis. BMJ (1995) 3.05
The challenge of integrating genetic medicine into primary care. BMJ (2001) 2.98
The new genetics. Implications for clinical services in Britain and the United States. BMJ (1998) 2.30
Primary care for patients at genetic risk. BMJ (1995) 2.10
Antenatal screening for carriers of cystic fibrosis: randomised trial of stepwise v couple screening. BMJ (1995) 2.06
Funding research in primary care: is Culyer the remedy? Br J Gen Pract (1997) 1.62
Screening for cystic fibrosis in primary care. BMJ (1993) 1.36
Patient attitudes to type specific serological tests in the diagnosis of genital herpes. Genitourin Med (1997) 1.27
The uptake and acceptability to patients of cystic fibrosis carrier testing offered in pregnancy by the GP. J Med Genet (1997) 1.26
Screening for carriers of cystic fibrosis--a general practitioner's perspective. BMJ (1993) 1.19
Genetics in primary care. Report on workshop of EC Concerted Action on Genetics Services in Europe (CAGSE) in association with the Royal College of GP Spring Meeting, Blackpool, UK, 28 April 1995. J Med Genet (1996) 1.13
Clinical genetics meets primary care. BMJ (1993) 1.12
Screening for carriers of cystic fibrosis. BMJ (1994) 1.12
Carrier screening in preconception consultation in primary care. J Community Genet (2011) 1.07
Screening for carriers of cystic fibrosis. Psychological consequences are unclear. BMJ (1994) 1.07
Expanding the role of the family history in primary care. Br J Gen Pract (1999) 1.01
The role of the general practitioner in cystic fibrosis. J R Soc Med (1999) 0.99
Genetic advances: great promise tempered with concern. Br J Gen Pract (1997) 0.98
The views of general practitioners on community carrier screening for cystic fibrosis. Br J Gen Pract (1996) 0.96
Pilot study of the acceptability of cystic fibrosis carrier testing during routine antenatal consultations in general practice. Br J Gen Pract (1996) 0.93
Costs, effects, and savings of screening for cystic fibrosis gene carriers. J Epidemiol Community Health (1998) 0.86
Direct marketing of cystic fibrosis carrier screening: commercial push or population need? J Med Genet (1995) 0.86
PCR-based screening for cystic fibrosis carrier mutations in an ethnically diverse pregnant population. Am J Hum Genet (1997) 0.82
Revalidation. Br J Gen Pract (1999) 0.78
Direct marketing of cystic fibrosis carrier screening: commercial push or population need? J Med Genet (1995) 0.75
Gender Differences in Clinical Presentations of Cystic Fibrosis Patients in Azeri Turkish Population. Tuberc Respir Dis (Seoul) (2016) 0.75
Implications for medical genetics of the House of Commons Science and Technology Committee's report on human genetics. J Med Genet (1996) 0.75
Identification of the cystic fibrosis gene: cloning and characterization of complementary DNA. Science (1989) 40.22
Development, multiplexing, and application of ARMS tests for common mutations in the CFTR gene. Am J Hum Genet (1992) 4.80
Cystic fibrosis carrier screening at first diagnosis of pregnancy in general practice. Lancet (1992) 2.16
Association of missense and 5'-splice-site mutations in tau with the inherited dementia FTDP-17. Nature (1998) 15.24
Possible prevention of neural-tube defects by periconceptional vitamin supplementation. Lancet (1980) 10.23
Effect of atenolol on mortality and cardiovascular morbidity after noncardiac surgery. Multicenter Study of Perioperative Ischemia Research Group. N Engl J Med (1996) 7.26
Report of the International Workshop on Screening for Breast Cancer. J Natl Cancer Inst (1993) 6.02
Rapid preparation of lymphocytes for tissue-typing. Lancet (1969) 5.11
The rational clinical examination. Does this patient have breast cancer? The screening clinical breast examination: should it be done? How? JAMA (1999) 4.80
Clinical features and natural history of von Hippel-Lindau disease. Q J Med (1990) 4.71
Characteristics relating to ovarian cancer risk: collaborative analysis of 12 US case-control studies. II. Invasive epithelial ovarian cancers in white women. Collaborative Ovarian Cancer Group. Am J Epidemiol (1992) 4.48
Complementary floral homeotic phenotypes result from opposite orientations of a transposon at the plena locus of Antirrhinum. Cell (1993) 4.47
Further experience of vitamin supplementation for prevention of neural tube defect recurrences. Lancet (1983) 4.02
Quantum annealing with manufactured spins. Nature (2011) 3.81
Waardenburg's syndrome patients have mutations in the human homologue of the Pax-3 paired box gene. Nature (1992) 3.63
A genetic study of type 2 neurofibromatosis in the United Kingdom. I. Prevalence, mutation rate, fitness, and confirmation of maternal transmission effect on severity. J Med Genet (1992) 3.63
Videotape-based decision aid for colon cancer screening. A randomized, controlled trial. Ann Intern Med (2000) 3.61
Von Hippel-Lindau disease: a genetic study. J Med Genet (1991) 3.61
One thousand health-related quality-of-life estimates. Med Care (2000) 3.53
Apparent prevention of neural tube defects by periconceptional vitamin supplementation. Arch Dis Child (1981) 3.45
Informed choice in genetic screening for thalassaemia during pregnancy: audit from a national confidential inquiry. BMJ (2000) 3.38
A clinical study of type 2 neurofibromatosis. Q J Med (1992) 3.23
Presymptomatic testing for Huntington's disease in the United Kingdom. The United Kingdom Huntington's Disease Prediction Consortium. BMJ (1992) 2.69
Apparent prevention of neural tube defects by periconceptional vitamin supplementation. 1981. Int J Epidemiol (2011) 2.68
Central venous catheters coated with minocycline and rifampin for the prevention of catheter-related colonization and bloodstream infections. A randomized, double-blind trial. The Texas Medical Center Catheter Study Group. Ann Intern Med (1997) 2.67
Factors associated with the starting of cigarette smoking by primary school children. Br J Prev Soc Med (1974) 2.61
Comparison of pregnancy outcome after amniocentesis for previous neural tube defect or raised maternal serum alphafetoprotein. Br J Obstet Gynaecol (1980) 2.50
Uptake of presymptomatic predictive testing for Huntington's disease. Lancet (1989) 2.49
Tissue typing using a routine one-step lymphocyte separation procedure. Br J Haematol (1970) 2.48
Stability of choices about life-sustaining treatments. Ann Intern Med (1994) 2.20
Outcome of unrelated donor bone marrow transplantation in 40 children with Hurler syndrome. Blood (1996) 2.19
BRAF mutation testing algorithm for vemurafenib treatment in melanoma: recommendations from an expert panel. Br J Dermatol (2013) 2.17
Sequence and analysis of chromosome 5 of the plant Arabidopsis thaliana. Nature (2000) 2.16
Cystic fibrosis carrier screening at first diagnosis of pregnancy in general practice. Lancet (1992) 2.16
Are patients of women physicians screened more aggressively? A prospective study of physician gender and screening. J Gen Intern Med (1995) 2.16
A worldwide assessment of the frequency of suicide, suicide attempts, or psychiatric hospitalization after predictive testing for Huntington disease. Am J Hum Genet (1999) 2.12
Thiopurine withdrawal during sustained clinical remission in inflammatory bowel disease: relapse and recapture rates, with predictive factors in 237 patients. Aliment Pharmacol Ther (2014) 2.11
Primary care for patients at genetic risk. BMJ (1995) 2.10
A report on genetic registers. Based on the report of the Clinical Genetics Society Working Party. J Med Genet (1978) 2.09
Substitution of a nursing-led inpatient unit for acute services: randomized controlled trial of outcomes and cost of nursing-led intermediate care. Age Ageing (2001) 2.07
Measuring the use of mammography: two methods compared. Am J Public Health (1992) 2.07
The characterization of novel, dual ErbB-2/EGFR, tyrosine kinase inhibitors: potential therapy for cancer. Cancer Res (2001) 2.06
Patient preferences for colon cancer screening. J Gen Intern Med (1999) 2.03
Long-term effect of bone-marrow transplantation for childhood-onset cerebral X-linked adrenoleukodystrophy. Lancet (2000) 1.98
Freeze-substitution of gram-negative eubacteria: general cell morphology and envelope profiles. J Bacteriol (1991) 1.92
Molecular characterisation of SMARCB1 and NF2 in familial and sporadic schwannomatosis. J Med Genet (2008) 1.87
Muscle disease in progressive systemic sclerosis: diagnostic and therapeutic considerations. Arthritis Rheum (1978) 1.83
Ethics of predictive testing for Huntington's chorea: the need for more information. Br Med J (Clin Res Ed) (1986) 1.83
Epitope mapping of the human immunodeficiency virus type 1 gp120 with monoclonal antibodies. J Virol (1988) 1.82
Family studies in RA - the importance of HLA-DR4 and of genes for autoimmune thyroid disease. J Rheumatol (1983) 1.82
Cerebral palsy and socioeconomic status: a retrospective cohort study. Arch Dis Child (2005) 1.77
Breast cancer among women in their forties: toward a reasonable research agenda. J Natl Cancer Inst (1994) 1.76
Genotypes at the GluR6 kainate receptor locus are associated with variation in the age of onset of Huntington disease. Proc Natl Acad Sci U S A (1997) 1.75
Patterns of exon deletions in Duchenne and Becker muscular dystrophy. Hum Genet (1988) 1.73
Isolation and growth of a Pseudomonas species that utilizes cyanide as a source of nitrogen. J Gen Microbiol (1983) 1.73
Studies on the formation of transfer ribonucleic acid-ribosome complexes. XXIV. Effects of antibiotics on binding of aminoacyl-oligonucleotides to ribosomes. J Biol Chem (1973) 1.69
Active immunotherapy used alone for maintenance of patients with acute myeloid leukaemia. Br Med J (1973) 1.67
Mutations in the PAX3 gene causing Waardenburg syndrome type 1 and type 2. Nat Genet (1993) 1.67
Pseudo-achondrogenesis with fractures. Clin Genet (1972) 1.66
Achondroplasia and thanatophoric dwarfism in the newborn. Clin Genet (1971) 1.65
Fibrinogen-coated albumin microcapsules reduce bleeding in severely thrombocytopenic rabbits. Nat Med (1999) 1.64
Leukaemia antigens and immunity in man. Nature (1973) 1.63
A clinical study of type 1 neurofibromatosis in north west England. J Med Genet (1999) 1.62
A genetic study of type 2 neurofibromatosis in the United Kingdom. II. Guidelines for genetic counselling. J Med Genet (1992) 1.62
A genetic register for von Hippel-Lindau disease. J Med Genet (1996) 1.61
Effects of counseling for late stage cancer patients. Cancer (1982) 1.55
Aggregates from mutant and wild-type alpha-synuclein proteins and NAC peptide induce apoptotic cell death in human neuroblastoma cells by formation of beta-sheet and amyloid-like filaments. FEBS Lett (1998) 1.55
Unusual fetal malformations after antiemetics in early pregnancy. Br Med J (1978) 1.54
Confidential inquiry into families with two siblings with cystic fibrosis. Arch Dis Child (1997) 1.54
Psychomotor, executive, and memory function in preclinical Huntington's disease. J Clin Exp Neuropsychol (2002) 1.51
The complete nucleotide sequence of the major adult beta globin gene of Xenopus laevis. J Biol Chem (1983) 1.50
Influence of oral creatine supplementation of muscle torque during repeated bouts of maximal voluntary exercise in man. Clin Sci (Lond) (1993) 1.50
Strong association between idiopathic membranous nephropathy and HLA-DRW3. Lancet (1979) 1.50
Cyclooxygenase-2 gene expression in human breast cancer. Int J Oncol (1997) 1.49
THE CIRCULATORY RESPONSES TO HYPERTHERMIA INDUCED BY RADIANT HEAT. J Clin Invest (1949) 1.48
Plants genetically modified to produce N-acylhomoserine lactones communicate with bacteria. Nat Biotechnol (1999) 1.48
Attitudes of patients after "genetic" termination of pregnancy. Br Med J (Clin Res Ed) (1981) 1.47
Genotype/phenotype correlations in type 2 neurofibromatosis (NF2): evidence for more severe disease associated with truncating mutations. J Med Genet (1998) 1.47
Mexican-American and Anglo-American attitudes toward organ donation. Transplant Proc (1988) 1.45
Characteristics relating to ovarian cancer risk: collaborative analysis of 12 US case-control studies. IV. The pathogenesis of epithelial ovarian cancer. Collaborative Ovarian Cancer Group. Am J Epidemiol (1992) 1.44
Type 2 neurofibromatosis: the need for supraregional care? J Laryngol Otol (1993) 1.42
Progress with gene-product mapping of the Mollicutes: Mycoplasma genitalium. Electrophoresis (1995) 1.41
States' use of transfer of custody as a requirement for providing services to emotionally disturbed children. Hosp Community Psychiatry (1991) 1.39
Effects of Iron and Chelating Agents on Dark Carboxylation Reactions in Plant Homogenates. Plant Physiol (1959) 1.39
A memorial tribute to Edward L. Bortz, M.D. J Am Geriatr Soc (1970) 1.38
Social cognition in frontotemporal dementia and Huntington's disease. Neuropsychologia (2003) 1.37
Comparison of amniotic-fluid and maternal serum alpha-fetoprotein levels in the early antenatal diagnosis of spina bifida and anencephaly. Lancet (1974) 1.37
Assignment of the locus for Waardenburg syndrome type I to human chromosome 2q37 and possible homology to the Splotch mouse. Am J Hum Genet (1990) 1.37
Ten years of presymptomatic testing for Huntington's disease: the experience of the UK Huntington's Disease Prediction Consortium. J Med Genet (2000) 1.35
Effects of the mutations Ala30 to Pro and Ala53 to Thr on the physical and morphological properties of alpha-synuclein protein implicated in Parkinson's disease. FEBS Lett (1998) 1.35
Adolescent suicidal behaviours: a population-based study of risk. Psychol Med (1997) 1.33
Inherited frontotemporal dementia in nine British families associated with intronic mutations in the tau gene. Brain (2002) 1.32
Missense mutations in the beta strands of the single A-domain of matrilin-3 result in multiple epiphyseal dysplasia. J Med Genet (2004) 1.30
Identification of a contaminating Mycobacterium tuberculosis strain with a transposition of an IS6110 insertion element resulting in an altered spoligotype. J Clin Microbiol (2001) 1.30
Update on the Manchester Scoring System for BRCA1 and BRCA2 testing. J Med Genet (2005) 1.29
Amplification of AML1 on a duplicated chromosome 21 in acute lymphoblastic leukemia: a study of 20 cases. Leukemia (2003) 1.28
Neural tube defect recurrence after 'partial' vitamin supplementation. J Med Genet (1989) 1.27
Partial trisomy 14q-- and pseudoxanthoma elasticum. Clin Genet (1973) 1.27
Molecular genetics in the National Health Service in Britain. J Med Genet (1989) 1.27